Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma
- PMID: 26918880
- DOI: 10.1097/MOT.0000000000000294
Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma
Abstract
Purpose of review: Several expanded criteria for liver transplantation for hepatocellular carcinoma (HCC) have been suggested out of concern that the Milan criteria may be too strict, and thereby exclude patients who could benefit from this surgical procedure. However, most expanded criteria were designed for deceased donor liver transplantation. Living donor liver transplantation (LDLT) differs from that of deceased donor liver transplantation primarily because LDLT liver grafts are not public resources.
Recent findings: In Asian countries, where HCC is endemic, LDLT is the main currently available treatment option for HCC. High-volume LDLT centers throughout Asia have adopted their own expanded selection criteria for LDLT for HCC with acceptable long-term results. Some centers utilize tumor markers as one of the criterion to help select suitable candidates. Indeed, such adjunctive biomarkers may have prognostic relevance for patients with HCC. The use of both biological and histomorphologic parameters may increase the number of transplantable patients.
Summary: The overall chance of survival, and recipient/donor preferences as well as the risk of recurrence are considered in the LDLT setting. Therefore, the selection criteria for liver transplantation for HCC could benefit from expansion for LDLT.
Similar articles
-
Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.Transplantation. 2014 Apr 27;97 Suppl 8:S20-3. doi: 10.1097/01.tp.0000446269.20934.d3. Transplantation. 2014. PMID: 24849825
-
Living donor liver transplantation for hepatocellular carcinoma.Recent Results Cancer Res. 2013;190:165-79. doi: 10.1007/978-3-642-16037-0_11. Recent Results Cancer Res. 2013. PMID: 22941020
-
Liver transplantation for hepatocellular carcinoma: Korean experience.J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):539-47. doi: 10.1007/s00534-009-0167-6. Epub 2009 Sep 2. J Hepatobiliary Pancreat Sci. 2010. PMID: 19727542 Review.
-
Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: the controversies continue.Dig Dis. 2007;25(4):296-8. doi: 10.1159/000106907. Dig Dis. 2007. PMID: 17960062
-
How far can we go with hepatocellular carcinoma in living donor liver transplantation?Curr Opin Organ Transplant. 2019 Oct;24(5):644-650. doi: 10.1097/MOT.0000000000000692. Curr Opin Organ Transplant. 2019. PMID: 31397731 Review.
Cited by
-
Liver transplantation for advanced hepatocellular carcinoma.Clin Mol Hepatol. 2016 Sep;22(3):309-318. doi: 10.3350/cmh.2016.0042. Epub 2016 Sep 25. Clin Mol Hepatol. 2016. PMID: 27729631 Free PMC article. Review.
-
When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.BMC Cancer. 2020 Aug 12;20(1):754. doi: 10.1186/s12885-020-07238-w. BMC Cancer. 2020. PMID: 32787864 Free PMC article.
-
New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.World J Gastroenterol. 2018 Oct 7;24(37):4230-4242. doi: 10.3748/wjg.v24.i37.4230. World J Gastroenterol. 2018. PMID: 30310256 Free PMC article. Review.
-
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.J Korean Med Sci. 2018 Oct 12;33(45):e283. doi: 10.3346/jkms.2018.33.e283. eCollection 2018 Nov 5. J Korean Med Sci. 2018. PMID: 30402048 Free PMC article.
-
Living donor liver transplantation for hepatocellular carcinoma in Seoul National University.Hepatobiliary Surg Nutr. 2016 Dec;5(6):453-460. doi: 10.21037/hbsn.2016.08.07. Hepatobiliary Surg Nutr. 2016. PMID: 28123999 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials